Time：2014-8-1 11:26:17　Browse：869次
A research achievement made by Hebei Yiling Hospital Affiliated to Hebei Medical University brings hope to the great many patients who are suffering from Myasthenia Gravis (MG), a worldwide intractable disease. The project of Science & Technology Department of Hebei Province---"Experimental and Clinical Study of TCM Zhongjiling Tablet in Treatment of Myasthenia Gravis " undertaken by this hospital has passed the expert team appraisal on Dec. 27th organized by the Science & Technology Department. This marks a major progress in TCM treatment of Myasthenia Gravis in our country.
Myasthenia Gravis is an autoimmune disease that mainly affects postsynaptic membrane of nerve-muscle juncture and a commonly occurred internal nerve disease according to epidemiologic data with an annual morbidity of 8/100,000. Clinical treatments are mainly cholinesterase inhibitors, immunosuppressants, thymectomy, serum exchange, γ immunoglobulin i.v. infusion, but no TCM treatment has ever been applied before. Experimental and clinical study on Zhongjiling Tablet in MG treatment is a new exploration of MG TCM therapy by the research team since 1980s. The innovative treatment based on the eight extra channels and collaterals therapeutic theory has developed into a diagnosis and treatment system that includes “analysis of the eight extra channels, diagnosis on the 5 visceras and treatment on the Sanjiao”, and it pointed out that “impotence of the eight extra channels and essential vigor deficiency” is the key factor to the MG pathogenesis and that the treatment should be “warming-up and regulating the extraordinary Yang, restoring the normal function and giving strength to the impotency”. Zhongjiling Tablet was prescribed accordingly and put into production and quality standard research, and many years' clinical applications has confirmed its favorable effect.
To further elucidate its mechanism, the experimental study of TCM Zhongjiling Tablet in Myasthenia Gravis treatment was carried out in cooperation with Beijing University of Chinese Medicine, and the result shows that Zhongjiling Tablet is able to improve the symptoms efficaciously on autoimmune MG rats. It may increase muscle strength, abate the muscle strength attenuation under continuous low frequency electric stimulation, inhibit the serum AchRab, and decrease ConA or N2Ach receptor-induced spleen lymphocyte proliferation. The result indicates that Zhongjiling Tablet has such outstanding advantages as bidirectional immunity regulation, and the experiments offer persuasive lab evidence for the clinical use of this drug against MG.
Zhongjiling Tablet has been clinically used by the Specialized Department of Myatrophy of Hebei Yiling Hospital for more than 10 years and has gained favorable effect. In order to evaluate the clinical effect of this drug objectively, a group of eye muscle MG and systemic MG patients were observed. According to the result, Zhongjiling group does not differ significantly from Prednisone positive control group in clinical effect score, decrease of AchRab titer and action potential attenuation percentage at the examined part, whereas obvious excellence of Zhongjiling group on the TCM symptoms improvement is observed. No side effect of liver dysfunction, preprandial serum glycose elevation, femoral head necrosis or central obesity is observed in Zhongjiling group.
It was the consensus of all experts in the appraisal committee that "Experimental and Clinical Study on TCM Zhongjiling Tablet in treatment of Myasthenia Gravis" was an internationally advanced achievement and they suggested further experimental and clinical study to elucidate the mechanism of Zhongjiling Tablet on immunity regulation and develop a national new drug soon.
It is known that the preclinical study on application for national new drug of this project has been generally finished, and the study on the mechanism of Zhongjiling Tablet's bidirectional regulation is still in process to discuss the bidirectional immunity regulatory function from multi-perspectives such as specified cell immunity, Th1 and Th2 imbalance, changes of related cytokines, gene expression and cell apoptosis. It shall initiate a new route for clinical MG treatment.